BACKGROUND: Historically, fewer than 5% of cancer patients enroll in clinical trials and lack of physician participation is a contributing factor. In 1999, the American College of Surgeons Oncology Group (ACOSOG) conducted a multicenter breast cancer trial evaluating the prognostic value of sentinel lymph node (SLN) and bone marrow micrometastases. This report elucidates factors influencing patient accrual. METHODS: Demographics of investigators (N = 198) and their success in accruing patients (N = 5327) were reviewed. ACOSOG Breast Committee members (N = 1136) were surveyed to identify factors influencing participation. RESULTS: Surgeons from 126 institutions participated in Z0010 (academic [48%], teaching-affiliated [20%], and community [29%] practices), and 28% of surgeons accrued 75% of the subjects. Twenty-four percent of surgeons accrued 75% of minority patients. Female surgeons accrued 24% of patients and accounted for 30% of investigators. On survey, 16% of respondents reported no prior experience with clinical trials and a number of factors were identified that influenced participation. CONCLUSIONS: ACOSOG successfully accrued 5327 patients to a SLN trial with surgeon participation from all practice settings. However, significant barriers to participation remain.
BACKGROUND: Historically, fewer than 5% of cancerpatients enroll in clinical trials and lack of physician participation is a contributing factor. In 1999, the American College of Surgeons Oncology Group (ACOSOG) conducted a multicenter breast cancer trial evaluating the prognostic value of sentinel lymph node (SLN) and bone marrow micrometastases. This report elucidates factors influencing patient accrual. METHODS: Demographics of investigators (N = 198) and their success in accruing patients (N = 5327) were reviewed. ACOSOG Breast Committee members (N = 1136) were surveyed to identify factors influencing participation. RESULTS: Surgeons from 126 institutions participated in Z0010 (academic [48%], teaching-affiliated [20%], and community [29%] practices), and 28% of surgeons accrued 75% of the subjects. Twenty-four percent of surgeons accrued 75% of minority patients. Female surgeons accrued 24% of patients and accounted for 30% of investigators. On survey, 16% of respondents reported no prior experience with clinical trials and a number of factors were identified that influenced participation. CONCLUSIONS: ACOSOG successfully accrued 5327 patients to a SLN trial with surgeon participation from all practice settings. However, significant barriers to participation remain.
Authors: Kathleen M Diehl; Erin M Green; Armin Weinberg; Wayne A Frederick; Dennis R Holmes; Bettye Green; Arden Morris; Henry M Kuerer; Robert A Beltran; Jane Mendez; Venus Gines; David M Ota; Heidi Nelson; Lisa A Newman Journal: Ann Surg Oncol Date: 2011-06-17 Impact factor: 5.344
Authors: Carrie N Klabunde; Nancy L Keating; Arnold L Potosky; Anita Ambs; Yulei He; Mark C Hornbrook; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2011-02-11 Impact factor: 13.506
Authors: Lee G Wilke; Karla V Ballman; Linda M McCall; Armando E Giuliano; Pat W Whitworth; Peter W Blumencranz; Douglas S Reintgen; William E Burak; A Marilyn Leitch; Kelly K Hunt Journal: Ann Surg Oncol Date: 2010-03-23 Impact factor: 5.344
Authors: Laurel C Trantham; William R Carpenter; Lisa D DiMartino; Brandolyn White; Melissa Green; Randall Teal; Giselle Corbie-Smith; Paul A Godley Journal: J Natl Med Assoc Date: 2015-12-02 Impact factor: 1.798
Authors: Lindsey Haynes-Maslow; Paul Godley; Lisa Dimartino; Brandolyn White; Janice Odom; Alan Richmond; William Carpenter Journal: Cancer Med Date: 2014-06-06 Impact factor: 4.452